Literature DB >> 9767203

Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results.

J Vignau1, E Brunelle.   

Abstract

The treatment of heroin addiction in France relies on either general practitioners (GP) or specialist Addiction Centres (ACs). In general, the GPs offer a more flexible approach regarding frequency of consultations, urine tests and dosing regimen while the AC approach is more structured. A cohort study was undertaken to compare the treatment strategies of buprenorphine therapy between these medical environments. To determine the efficacy of each treatment, a number of outcomes were measured including the Addiction Severity Index, retention rates at 90 and 180 days, the average dose prescribed, quality of life assessment, body weight and two self-reported measures: treatment perception and predictive total duration. A total of 69 patients were enrolled; 32 treated by GPs and 37 treated in ACs. Significant differences, including average age, addiction severity and employment status were apparent between each group. Nevertheless, significant improvements in the social and medical status were observed in all patients after 3 months, continuing after 6 months in both groups. Treatment retention was good in both groups with 65% of the total sample remaining after 180 days. The usually more flexible GP approach was more rigid in this study, resulting in an equally positive treatment outcome as seen in the ACs. The study highlights the effectiveness of buprenorphine in addicts with different social and medical backgrounds, regardless of the therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767203     DOI: 10.1159/000052038

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  11 in total

1.  Policy progress for physician treatment of opiate addiction.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Buprenorphine: a potential new treatment option for opioid dependence.

Authors:  Anita Srivastava; Meldon Kahan
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

Review 3.  Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?

Authors:  Erik W Gunderson; David A Fiellin
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

5.  Prescription opioid use and misuse: piloting an educational strategy for rural primary care physicians.

Authors:  Anita Srivastava; Meldon Kahan; Ashifa Jiwa
Journal:  Can Fam Physician       Date:  2012-04       Impact factor: 3.275

6.  The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales.

Authors:  John Strang; Janie Sheridan; Claire Hunt; Bethanne Kerr; Clare Gerada; Michael Pringle
Journal:  Br J Gen Pract       Date:  2005-06       Impact factor: 5.386

Review 7.  Buprenorphine: new treatment of opioid addiction in primary care.

Authors:  Meldon Kahan; Anita Srivastava; Alice Ordean; Sharon Cirone
Journal:  Can Fam Physician       Date:  2011-03       Impact factor: 3.275

Review 8.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 9.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Comparison of prescriber evaluations and patient-directed self-reports in office-based practice for buprenorphine treatment of opiate-dependent individuals in France, 2002.

Authors:  Estelle Lavie; Mélina Fatséas; Jean-Pierre Daulouède; Cécile Denis; Jacques Dubernet; Laurent Cattan; Marc Auriacombe
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.